Chicago, Illinois
Cancer clinical trials in Chicago, IL
337 cancer studies are recruiting participants at sites in Chicago as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Chicago at a glance
- 337 studies are recruiting at a site in Chicago.
- By phase: Early Phase 1 (5), Phase 1 (51), Phase 1/2 (45), Phase 2 (82), Phase 2/3 (7), Phase 3 (86), Phase 4 (4), No phase (28), Observational (29). Studies of devices and behavioral approaches have no phase.
- By sponsor: university, hospital or other (153), industry (152), government (32).
- By research area: Lung Cancer (95), Breast Cancer (87), Lymphoma (80), Prostate Cancer (39), Pancreatic Cancer (21), Melanoma (15).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in Chicago
Basic details from each study's public record (the 30 most recently updated of 337). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
BRE-13: Mediterranean Diet
- No phase
- Ages 18 to 80
- Female participants
- Sponsor
- University of Illinois Chicago
- Study site
- University of Illinois at Chicago Campus
- Registry record
- NCT07869355 · updated
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- John H Stroger Jr Hospital of Cook County
- Registry record
- NCT03418961 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Advocate Illinois Masonic Medical Center · John H Stroger Jr Hospital of Cook County · Mount Sinai Hospital Medical Center
- Registry record
- NCT05564377 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Chicago, IL on ClinicalTrials.gov.
Lung cancer studies recruiting in Chicago
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Chicago Comprehensive Cancer Center
- Registry record
- NCT06287775 · updated
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase 3
- Ages 18 to 100
- All sexes
- Sponsor
- Amgen
- Study site
- University of Illinois Chicago
- Registry record
- NCT05920356 · updated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- University of Chicago
- Registry record
- NCT07659782 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Advocate Illinois Masonic Medical Center · John H Stroger Jr Hospital of Cook County · University of Chicago Comprehensive Cancer Center
- Registry record
- NCT04267848 · updated
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Chicago Comprehensive Cancer Center
- Registry record
- NCT04665739 · updated
Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers
- Observational
- All ages
- All sexes
- Sponsor
- Lung Cancer Mutation Consortium
- Study site
- Northwestern University
- Registry record
- NCT04712877 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Chicago, IL on ClinicalTrials.gov.
Prostate cancer studies recruiting in Chicago
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Northwestern University · Rush MD Anderson Cancer Center · University of Illinois
- Registry record
- NCT04423211 · updated
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- University of Chicago Medical Center ( Site 0045) · University of Illinois at Chicago ( Site 0105)
- Registry record
- NCT06136624 · updated
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Rush MD Anderson Cancer Center · University of Chicago Comprehensive Cancer Center
- Registry record
- NCT03866382 · updated
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Northwestern University
- Registry record
- NCT05691465 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Chicago, IL on ClinicalTrials.gov.
Melanoma studies recruiting in Chicago
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Northwestern University · Swedish Covenant Hospital
- Registry record
- NCT07068074 · updated
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Phase 1/2
- From 6 months, up to 17 years
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Call for Information (Investigational Site 0024)
- Registry record
- NCT02332668 · updated
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Northwestern University · University of Illinois
- Registry record
- NCT05136196 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Chicago, IL on ClinicalTrials.gov.
Lymphoma studies recruiting in Chicago
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Study site
- Northwestern
- Registry record
- NCT05289687 · updated
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Nurix Therapeutics, Inc.
- Study site
- The University of Chicago
- Registry record
- NCT07221500 · updated
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Phase 1
- Ages 0 to 18
- All sexes
- Sponsor
- Autolus Limited
- Study site
- Lurie Children's Hospital
- Registry record
- NCT06173518 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Chicago Medical Center ( Site 0126)
- Registry record
- NCT06890884 · updated
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT07109219 · updated
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Northwestern University · University of Chicago Comprehensive Cancer Center · University of Illinois
- Registry record
- NCT03739814 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Northwestern University · University of Chicago Comprehensive Cancer Center
- Registry record
- NCT04269902 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Lurie Children's Hospital-Chicago · University of Chicago Comprehensive Cancer Center · University of Illinois
- Registry record
- NCT04546399 · updated
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Chicago Comprehensive Cancer Center
- Registry record
- NCT05272384 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Advocate Illinois Masonic Medical Center · Lurie Children's Hospital-Chicago · Mount Sinai Hospital Medical Center
- Registry record
- NCT05675410 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Chicago, IL on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Chicago
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Phase 2
- Ages 12 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130)
- Registry record
- NCT04924075 · updated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- University of Chicago
- Registry record
- NCT07644559 · updated
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- University of Chicago Comprehensive Cancer Center · University of Illinois
- Registry record
- NCT04858334 · updated
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Northwestern University
- Registry record
- NCT05372614 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Chicago, IL on ClinicalTrials.gov.
Ask about studies near Chicago
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections